Accessibility links Skip to main content

How would you review a PQR as a virtual QP

Reviewing a Product Quality Review (PQR) as a virtual Qualified Person (QP) requires a systematic approach to ensure thoroughness, accuracy, and compliance. Here is a streamlined and effective way to conduct the review:

Contact us

Fill out the form and we will contact you shortly.

Naam
Privacy Policy 
Continue reading
  1. Preparation

1.1 Understand the Context

  • Scope and Objective: Familiarize yourself with the purpose and scope of the PQR, including the specific process being qualified.
  • Regulatory Requirements: Review relevant regulatory guidelines and company SOPs to understand the compliance framework.
  1. Initial Document Assessment

2.1 Verify Document Completeness

  • Sections: Ensure all required sections of the PQR are present (e.g., introduction, methodology, results, discussion, conclusions, and appendices).
  • Signatures: Check for necessary approvals and signatures to confirm that the report has been reviewed internally before reaching you.
  1. Detailed Content Review

3.1 Protocol Adherence

  • Protocol Compliance: Verify that the qualification activities were conducted according to the approved protocol.
  • Deviation Handling: Ensure any deviations from the protocol are documented, justified, and resolved.

3.2 Methodology Evaluation

  • Sampling Plan: Assess the adequacy of the sampling plan and ensure it appropriately represents the process.
  • Analytical Methods: Confirm that analytical methods used are validated and suitable for their intended purpose.

3.3 Data Review

  • Raw Data Verification: Check the accuracy and completeness of raw data entries.
  • Result Interpretation: Evaluate the data analysis and ensure results meet predefined acceptance criteria.
  • Statistical Analysis: Review statistical methods used and ensure they are appropriate and correctly applied.

 

 

  1. Critical Analysis

4.1 Deviation and Non-Conformance Management

  • Identification and Documentation: Ensure all deviations and non-conformances are identified and documented.
  • Impact Assessment: Evaluate the impact of deviations on the qualification outcome.
  • Corrective Actions: Review the effectiveness of corrective and preventive actions (CAPA).

4.2 Risk Assessment

  • Risk Analysis: Conduct a risk assessment to evaluate any potential impact on product quality or patient safety.
  • Risk Mitigation: Ensure appropriate risk mitigation measures are implemented and documented.
  1. Conclusions and Recommendations

5.1 Summary of Findings

  • Consolidate Findings: Summarize the key findings of the review, highlighting any issues and their resolutions.
  • Draw Conclusions: Provide clear conclusions on whether the process meets the qualification criteria.

5.2 Recommendations

  • Approval: Recommend the approval or rejection of the PQR based on the review.
  • Further Actions: Suggest any additional actions required, such as requalification, additional testing, or process improvements.
  1. Documentation and Reporting

6.1 Review Report

  • Document Review Notes: Keep detailed notes of your review, including any comments, questions, and decisions.
  • Prepare Review Summary: Create a comprehensive review report summarizing the review process, findings, and recommendations.

6.2 Communication

  • Stakeholder Communication: Communicate findings and recommendations to relevant stakeholders (e.g., manufacturing, quality assurance, regulatory affairs).
  • Follow-Up Actions: Ensure follow-up on any required actions based on your recommendations.
  1. Final Approval
  • Sign-Off: Provide your final approval or disapproval of the PQR.
  • Record Keeping: Ensure all documents related to the PQR review are properly archived for future reference and regulatory audits.

Tools and Best Practices

  • Collaboration Tools: Use virtual collaboration tools (e.g., shared document platforms, video conferencing) to communicate with the team and review documents.
  • Checklists: Utilize checklists to ensure all aspects of the PQR are reviewed systematically.
  • Regular Updates: Provide regular updates to stakeholders to keep them informed of the review progress.

 

By following these steps and leveraging virtual collaboration tools, a virtual QP can effectively and efficiently review a PQR, ensuring compliance with regulatory standards and maintaining the integrity of the qualification process.

Your partner in quality, safety, and compliance

The life sciences sector requires specialized knowledge and reliable support. With our broad expertise, we help organizations comply with laws and regulations, ensure quality, and continue to innovate with confidence.

Related services

QP Services

Clinical QP Services

Related articles

07 Apr 2026

MIAS Pharma will be attending the BIO International Convention in San Diego, USA

MIAS Pharma is excited to attend the BIO International convention in San Diego, California, from June 22nd – 25th 2026. Visit us at booth #4052, we’ll be happy to connect.

01 Apr 2026

Let’s Meet at SNMMI Annual meeting 2026 LA

MIAS Pharma is excited to attend the SNMMI annual meeting in Los Angeles, California, from May 30th – June 2nd 2026. Visit us at booth #1363, we’ll be happy to connect.

20 Mar 2026

Labelling & Packaging: A Core MAH Responsibility

Marketing Authorisation Holders (MAHs) carry primary responsibility for the accuracy, control, and lifecycle management of labelling and packaging across all markets where a product is placed on the EU/EEA market. This obligation extends beyond artwork creation to encompass regulatory approval, change control, supply chain implementation, and post‑market vigilance for labelling‑related quality defects and recalls.

06 Mar 2026

MAHs: Are Your GMP–GVP Interfaces Aligned?

Calling all Marketing Authorisation Holders (MAHs) are you set up for success? Have you confirmed whether your five‑year renewal is required? Is this critical information visible and accessible to your QPs and QPPVs?

27 Feb 2026

MIAS Pharma: End to End MAH services for Virtual and Rare Disease Companies

For small and virtual companies, especially those developing rare disease medicines, the requirements of acting as a Marketing Authorisation Holder (MAH) in the EU can feel overwhelming. EU legislation places the MAH at the centre of responsibility for the quality, safety and efficacy of the product throughout its lifecycle, regardless of how many activities are outsourced. MIAS Pharma is designed to be your one integrated partner in Europe: an established presence with the expertise, infrastructure and network to assume day‑to‑day MAH obligations on your behalf while you focus on science, patients and portfolio strategy.

20 Feb 2026

Quality & Regulatory Implications from EU Critical Medicines Act

The European pharmaceutical landscape is entering a period of major regulatory transformation with the introduction of not only the EU Critical Medicines Act (CMA), new pharma package.

28 Jan 2026

Navigating Evolving EU Marketing Authorisation: Are You Ready for Tomorrow’s Compliance?

As the European pharmaceutical landscape transforms, Marketing Authorisation Holders (MAHs) now face a broader – and more demanding – array of duties that stretch far beyond initial product approval. The new compliance reality encompasses critical operational areas like shortage reporting, environmental risk management, end-to-end product data maintenance, supply chain resilience, and more. These obligations often overlap with, yet are legally distinct from, manufacturing and wholesale authorisations – presenting new blind spots and risks for the unprepared.